Mission

We design, engineer and apply unique biosensors. These genetically encoded reporters are used to validate drug candidates and to enhance the development of personalized cancer drugs. Our mission is to contribute to the identification of the most effective drug to accelerate HIT-to-LEAD development.

KinCon-biolabs

Research

The KinCon biolabs project at the TKFI aims to identify efficient mutation-specific drug candidates for kinases. In addition, we are trying to reactivate tumor suppressor kinases that are inactivated in lung cancer.

In a second project, we aim to modulate a signalling cascade that plays a crucial role in the development of neurodegenerative diseases. Here our focus is to identify new approaches and treatment options.

Research Team Members

Philipp Tschaikner, Ph.D.

CSO

philipp.tschaikner@kincon-biolabs.eu

Priv. Doz. Dr. Eduard Stefan

CEO | Principal Investigator

eduard.stefan@tkfi.at 

Dipl.-Ing. Alexandra Fritz

Research Associate

alexandra.fritz@kincon-biolabs.eu

OUR AIM IS TO FURTHER COMPREHEND THE MOLECULAR FACTORS BEHIND THE ONSET OF CANCER.

Make a donation now

Publications

Selected Publications

  • Guerin, N., Feichtner, A., Stefan, E., Kaserer, T., & Donald, B. R. Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. Cell Systems, 13(10), 830-843. (2022).
  • Fleischmann, J., Feichtner, A., DeFalco, L., Kugler, V., Schwaighofer, S., Huber, R. G., & Stefan, E.* Allosteric kinase inhibitors reshape MEK1 kinase activity conformations in cells and in silico. Biomolecules, 11(4), 518. (2021).
  • Mayrhofer, J. E., Enzler, F., Feichtner, A., Röck, R., Fleischmann, J., Raffeiner, A., Tschaikner, P., Ogris, E., Huber, R. G., Hartl, M., Schneider, R., Troppmair, J., Torres-Quesada, O., & Stefan, E.* Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. PNAS, 117(49), 31105-31113. (2020).
  • Röck, R., Mayrhofer, J. E., Torres-Quesada, O., Enzler, F., Raffeiner, A., Raffeiner, P., Feichtner, A., Huber, R. G., Koide, S., Taylor, S. S., Troppmair, J., & Stefan, E.* BRAF inhibitors promote intermediate BRAF (V600E) conformations and binary interactions with activated RAS. Science Advances, 5(8), eaav8463. (2019).

* Kommunizierende Autoren

All Publications

https://pubmed.ncbi.nlm.nih.gov/?term=Eduard+Stefan+or+Philipp+Tschaikner&sort=date&size=200

Funds

Links

https://www.uibk.ac.at/biochemistry/people/stefan/